Journal of Biomedical Advancement Scientific Research

Abstract

Ferroptosis is an iron-dependent form of regulated cell death driven by uncontrolled phospholipid peroxidation and collapse of cellular lipid-antioxidant defenses. Its involvement in ischemia–reperfusion injury, acute kidney injury, myocardial injury, ischemic stroke, acute lung injury, sepsis, and other inflammatory disorders has created substantial interest in pharmacological ferroptosis suppression. Tocotrienols, naturally occurring members of the vitamin E family that are particularly abundant in palm-derived tocotrienol-rich fractions, possess an unsaturated isoprenoid side chain that distinguishes them structurally and functionally from tocopherols. A major advance emerged in 2026 when direct comparative experiments demonstrated that tocotrienols suppressed pharmacologically and genetically induced ferroptosis at substantially lower concentrations than tocopherols. This qualitative literature review integrates this new evidence with contemporary knowledge of GPX4, system Xc−, FSP1–CoQ10, GCH1–BH4, DHODH, iron metabolism, ACSL4/LPCAT3-mediated phospholipid remodeling, and mitochondrial redox biology. Particular attention is given to renal, cardiac, cerebral, pulmonary, and systemic acute injury. The review argues that tocotrienols should increasingly be considered membrane-level radical-trapping ferroptosis suppressors rather than merely nonspecific antioxidants. However, direct clinical evidence remains absent, and translation is constrained by bioavailability, tissue exposure, isoform differences, timing, formulation, and biomarker limitations. A further therapeutic paradox emerges because ferroptosis inhibition may protect acutely injured normal tissues while potentially opposing ferroptosis-based anticancer strategies. Carefully designed pharmacokinetic, biomarker, organ-specific, and early-phase clinical studies are therefore required before palm tocotrienols can be positioned as clinically validated ferroptosis-targeted interventions.